Compare AMBP & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMBP | AGIO |
|---|---|---|
| Founded | 2021 | 2007 |
| Country | Luxembourg | United States |
| Employees | 6500 | N/A |
| Industry | Containers/Packaging | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.2B |
| IPO Year | N/A | 2013 |
| Metric | AMBP | AGIO |
|---|---|---|
| Price | $4.80 | $37.19 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 7 | 8 |
| Target Price | $4.39 | ★ $38.88 |
| AVG Volume (30 Days) | ★ 2.2M | 1.1M |
| Earning Date | 04-23-2026 | 04-29-2026 |
| Dividend Yield | ★ 10.39% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $43,011,000.00 |
| Revenue This Year | $7.31 | $76.75 |
| Revenue Next Year | $2.53 | $170.73 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.29 | $22.24 |
| 52 Week High | $5.03 | $46.00 |
| Indicator | AMBP | AGIO |
|---|---|---|
| Relative Strength Index (RSI) | 74.97 | 73.51 |
| Support Level | $3.90 | $36.43 |
| Resistance Level | $5.00 | $43.72 |
| Average True Range (ATR) | 0.16 | 1.55 |
| MACD | 0.04 | 0.42 |
| Stochastic Oscillator | 98.04 | 91.94 |
Ardagh Metal Packaging SA is a supplier of infinitely recyclable, sustainable, metal beverage cans and ends to brand owners. The company deals with multiple categories of products including beer, carbonated soft drinks, energy drinks, hard seltzers, juices, pre-mixed cocktails, teas, sparkling waters, and wine. The geographical segments of the company includes Europe and the Americas. Geographically, the company derives a majority of its revenue from the United States.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.